TRexBio — Third Quarter 2026 Earnings Summary

TRexBio reported a net loss of $13.2 million for the third quarter of 2026, driven by increased research and development expenses related to its TRB-061 and TRB-071 programs. The company announced positive Phase 1a results for TRB-061, an investigational TNFR2 agonist for atopic dermatitis, which demonstrated proof of mechanism and safety in healthy volunteers. TRexBio completed a $133.5 million initial public offering in October 2026, extending its cash runway into the second half of 2029. Topline data for the Phase 1b trial of TRB-061 is expected in mid-2027, while a Phase 1 trial for the CD30 agonist TRB-071 is anticipated to begin in the first half of 2027.